Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VK may become a single ticket operator for the Pushkin Card

6/27/23 VKCO

Dmitry Maksimov resigned from the Positive Technologies Board of Directors

6/27/23 POSI

Shareholders of Stavropolenergosbyt approved dividends for 2022

6/26/23 STSB

Floating LNG storage facility for Novatek Saam FSU came to Russia

6/26/23 NVTK

Carnival reported six months of 2023

6/26/23 CCL

FinEx plans to cross-list ETFs in a friendly jurisdiction to unlock

6/26/23 MOEX

MD Medical receipts will continue to be traded on the Moscow Exchange until September 30

6/26/23 MDMG

Shareholders of Mordovian Energy Supply Company approved dividends for 2022

6/26/23 MRSB

LSR sold land on Vasilievsky Island to the developer Legenda

6/26/23 LSRG

Arctic LNG-2 has risen to $25 billion

6/26/23 NVTK